Cost-Effectiveness Analysis of Siltuximab for Australian Public Investment in the Rare Condition Idiopathic Multicentric Castleman Disease.

Francis Shupo Keith R Abrams Zanfina AdemiGrace Wayi-WayiNatasa ZibelnikMatt Kirchmann Carolyn Rutherford Kelly Makarounas-Kirchmann

Published in: PharmacoEconomics - open (2023)

Within a collaborative and inclusive stakeholder framework, the model submitted to the Australian PBAC found siltuximab to be cost-effective for the treatment of iMCD.

Keyphrases

healthcare
mental health
emergency department
smoking cessation
combination therapy
drug induced